Gedeon Richter says it aims to continue expanding the geographical footprint for its Terrosa (teriparatide) biosimilar of Eli Lilly’s Forsteo, following the product’s recent expansion into a trio of new markets: South Korea, Canada, and Israel.
Following launch in Europe and Japan in 2019, the latter via local partner Mochida Pharmaceuticals, the Hungarian firm launched Terrosa...






